Canakinumab for treatment of adult-onset Still's disease to achieve reduction of arthritic manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled trial

Key Findings

• ●67% canakinumab vs 41% placebo achieved primary endpoint (p=0.18, underpowered)
• ●Trial terminated prematurely due to disease rarity and EMA conditional approval

Referenced in (1 disease)